Journal of Crohn s and Colitis · 2010 · 103 citations · 293 references
MedicineImmunologyPharmacotherapyGastroenterologyImmunizationImmunotherapyAdverse Events Following ImmunizationGastrointestinal ImmunologyGastrointestinal ToxicityImmunotherapy SafetyInflammatory Bowel DiseaseIntestinal ObstructionConcomitant Medication EffectsConcomitant TherapyInflammatory Bowel Disease TherapyInfusion-related ReactionsIntestinal StricturesNonsteroidal Anti-inflammatory Drug SafetyOpportunistic Viral InfectionsSerious Adverse Events
Infliximab (IFX) has tremendously enriched the therapy of inflammatory bowel diseases (IBD) and other immune mediated diseases. Although the efficacy of IFX was undoubtedly proven during the last decade numerous publications have also caused various safety concerns. To summarize the immense information concerning adverse events and safety issues the Austrian Society of Gastroenterology and Hepatology launched this evidence based consensus on the safe use of IFX which covers the following topics: infusion reactions and immunogenicity, skin reactions, opportunistic infections (including tuberculosis), non-opportunistic infections (bacterial and viral), vaccination, neurological complications, hepatotoxicity, congestive heart failure, haematological side effects, intestinal strictures, stenosis and bowel obstruction (SSO), concomitant medication, malignancy and lymphoma, IFX in the elderly and the young, mortality, fertility, pregnancy and breast feeding. To make the vast amount of information practicable for routine application the consensus was finally condensed into a checklist for a safe use of IFX which consists of two parts: issues to be addressed prior to anti-TNF therapy and issues to be addressed during maintenance. Both parts are further divided into obligatory and facultative items.
293
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein et al. · The Lancet · 2002 · 4.2K citations
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Paul Rutgeerts, William J. Sandborn, Brian G. Feagan et al. · New England Journal of Medicine · 2005 · 3.9K citations · Full text
Christopher Dye, S Scheele, Vikram Pathania et al. · JAMA · 1999 · 3K citations
Public Health, Infectious Disease Control, Infectious Diseases +17